Mesoblast Limited General and Administrative Expenses | MESO

General and Administrative Expenses — these are a part of a company's operating expenses that are not directly related to the production of goods or the provision of services but are necessary for the overall functioning of the business.

What these expenses include

Salaries of administrative staff (executives, HR, accountants, legal personnel)
Office rent and utilities
Office equipment and IT infrastructure
Professional services (auditors, lawyers, consultants)
Insurance
General administrative travel and representation expenses

What the metric indicates

Cost control
A high level of such expenses may indicate inefficient management or an overly complex structure
Profitability
Reducing administrative expenses while maintaining stable revenue increases operating profit
Comparative analysis
Investors can compare this metric as a percentage of revenue among companies in the same industry
Business flexibility
Companies with a flexible and controlled expense structure are more resilient to revenue declines

Annual General and Administrative Expenses Mesoblast Limited

2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
39.3 M	25 M	27.5 M	-	-	-	21.6 M	21.9 M	23 M	22.5 M	36.2 M	26.6 M	30.7 M	28.1 M	11.8 M

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
39.3 M	11.8 M	26.2 M

Quarterly General and Administrative Expenses Mesoblast Limited

2025-Q4	2025-Q2	2024-Q4	2024-Q2	2023-Q4	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
28.5 M	39.3 M	18 M	25 M	-	27.5 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
39.3 M	18 M	27.7 M

General and Administrative Expenses of other stocks in the Biotechnology industry

Issuer	General and Administrative Expenses	Price	% 24h	Market Cap	Country
Stoke Therapeutics STOK	67.1 M	$ 25.32	0.8 %	$ 1.5 B	USA
Sutro Biopharma STRO	41 M	$ 15.13	0.23 %	$ 129 M	USA
Shattuck Labs STTK	17.2 M	$ 6.5	1.04 %	$ 452 M	USA
Supernus Pharmaceuticals SUPN	486 M	$ 42.76	0.9 %	$ 2.41 B	USA
Sesen Bio SESN	22.1 M	-	7.29 %	$ 127 M	USA
Savara SVRA	42.1 M	$ 4.78	0.1 %	$ 1.06 B	USA
China SXT Pharmaceuticals SXTC	223 K	$ 2.08	1.99 %	$ 1.41 M	China
Takeda Pharmaceutical Company Limited TAK	965 B	$ 17.81	0.08 %	$ 28.1 B	Japan
Protara Therapeutics TARA	21.9 M	$ 2.63	0.36 %	$ 113 M	USA
Tarsus Pharmaceuticals TARS	427 M	$ 74.46	1.99 %	$ 3.11 B	USA
Bio-Techne Corporation TECH	452 M	$ 72.58	0.25 %	$ 11.3 B	USA
Tenax Therapeutics TENX	23.7 M	$ 1.96	2.59 %	$ 76.9 M	USA
Teva Pharmaceutical Industries Limited TEVA	1.29 B	$ 39.66	0.33 %	$ 45.4 B	Israel
TG Therapeutics TGTX	232 M	$ 53.91	0.12 %	$ 7.78 B	USA
Tonix Pharmaceuticals Holding Corp. TNXP	87.7 M	$ 8.07	0.54 %	$ 68.7 M	USA
Trevi Therapeutics TRVI	15.8 M	$ 13.72	0.99 %	$ 1.85 B	USA
Taysha Gene Therapies TSHA	33.9 M	$ 4.49	0.11 %	$ 1.44 B	USA
UroGen Pharma Ltd. URGN	155 M	$ 42.78	3.33 %	$ 2.06 B	Israel
United Therapeutics Corporation UTHR	756 M	$ 536.4	0.37 %	$ 23.8 B	USA
Vericel Corporation VCEL	76.8 M	$ 41.07	2.29 %	$ 2.07 B	USA
Veracyte VCYT	111 M	$ 47.67	4.06 %	$ 3.75 B	USA
Vir Biotechnology VIR	92.1 M	$ 11.78	5.46 %	$ 1.63 B	USA
Viking Therapeutics VKTX	48.4 M	$ 29.28	0.36 %	$ 3.3 B	USA
Vanda Pharmaceuticals VNDA	238 M	$ 4.58	0.51 %	$ 270 M	USA
Verrica Pharmaceuticals VRCA	35.2 M	$ 4.31	0.21 %	$ 45.9 M	USA
Vertex Pharmaceuticals Incorporated VRTX	1.75 B	$ 503.5	0.07 %	$ 129 B	USA
Verastem VSTM	81.1 M	$ 8.0	3.9 %	$ 554 M	USA
VistaGen Therapeutics VTGN	18.4 M	$ 0.26	0.21 %	$ 9.9 M	USA
vTv Therapeutics VTVT	14.9 M	$ 30.33	0.59 %	$ 120 M	USA
Voyager Therapeutics VYGR	37.5 M	$ 2.46	0.41 %	$ 144 M	USA
Wave Life Sciences Ltd. WVE	75.3 M	$ 3.75	0.66 %	$ 632 M	Singapore
Xenetic Biosciences XBIO	2.75 M	$ 2.2	0.45 %	$ 3.74 M	USA
XBiotech XBIT	8.3 M	$ 2.18	0.23 %	$ 66.5 M	USA
Exicure XCUR	6.83 M	$ 1.07	3.48 %	$ 6.74 M	USA
Xenon Pharmaceuticals XENE	26.8 M	$ 37.57	4.68 %	$ 2.98 B	Canada
Xeris Pharmaceuticals XERS	182 M	$ 10.13	11.56 %	$ 1.63 B	USA
X4 Pharmaceuticals XFOR	43.5 M	$ 2.9	2.47 %	$ 123 M	USA
Xencor XNCR	63.6 M	$ 25.63	3.18 %	$ 1.9 B	USA
22nd Century Group XXII	7.59 M	$ 0.91	2.13 %	$ 168 K	USA
Zai Lab Limited ZLAB	278 M	$ 25.62	5.3 %	$ 28.1 B	China
Zentalis Pharmaceuticals ZNTL	37.7 M	$ 2.78	10.32 %	$ 200 M	USA
Zoetis ZTS	2.38 B	$ 71.41	2.45 %	$ 31.7 B	USA
Alterity Therapeutics Limited ATHE	5.48 M	$ 3.22	1.09 %	$ 20.6 B	Australia
Dr. Reddy's Laboratories Limited RDY	93.9 B	$ 12.32	0.57 %	$ 10.3 B	India
Mirati Therapeutics MRTX	240 M	-	-	$ 3.3 B	USA
Gritstone Oncology GRTS	28.8 M	-	0.42 %	$ 213 M	USA
NexImmune NEXI	13 M	-	70.13 %	$ 4.12 M	USA
Harpoon Therapeutics HARP	18.8 M	-	-	$ 763 M	USA
InVivo Therapeutics Holdings Corp. NVIV	5.42 M	-	-37.48 %	$ 476 K	USA
Nymox Pharmaceutical Corporation NYMX	1 M	-	-19.68 %	$ 18.4 M	Canada